Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential
Affiliation
Cancer Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF) , Doha, Qatar.Issue Date
2020
Metadata
Show full item recordAbstract
Introduction: Immune checkpoint inhibitors (ICIs) have shown a great therapeutic efficacy in cancer patients. However, a significant proportion of cancer patients remain unresponsive or show limited response. T cell immunoglobulin and mucin-domain containing protein-3 (TIM-3) is a co-inhibitory receptor expressed on various cell types and is involved in the attenuation of immune responses. TIM-3 and its ligands are highly expressed in various solid malignancies and some studies have reported its association with worse disease outcomes. Thus, targeting TIM-3 could be a promising therapeutic approach to treat cancer patients. Areas covered: This review describes the role of TIM-3 and its ligands in regulating anti-tumor immunity and their contribution to cancer progression. Moreover, this review focuses on the preclinical models and translational data from important studies published in PubMed till October 2020, which demonstrate the therapeutic benefits of targeting TIM-3 signaling. Expert opinion: Despite the promising data obtained from targeting TIM-3 in preclinical models, precise mechanisms underlying the anti-tumor effects of TIM-3 inhibition are not fully elucidated. Therefore, mechanistic studies are required to provide better insights into the anti-tumor effects of targeting TIM-3, and clinical data are necessary to determine the safety profiles and therapeutic efficacy of TIM-3 inhibition in cancer patients.Citation
Saleh R, Toor SM, Elkord E. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. Expert Opin Ther Targets. 2020:1-12.Journal
Expert Opinion on Therapeutic TargetsDOI
10.1080/14728222.2020.1841750PubMed ID
33103506Additional Links
https://dx.doi.org/10.1080/14728222.2020.1841750Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1080/14728222.2020.1841750
Scopus Count
Collections
Related articles
- TIM-3 pathway dysregulation and targeting in cancer.
- Authors: Zeidan AM, Komrokji RS, Brunner AM
- Issue date: 2021 May
- Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy.
- Authors: Cao Y, Li Q, Liu H, He X, Huang F, Wang Y
- Issue date: 2021
- Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
- Authors: Saleh R, Toor SM, Al-Ali D, Sasidharan Nair V, Elkord E
- Issue date: 2020 Jun 25
- New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.
- Authors: Gomes de Morais AL, Cerdá S, de Miguel M
- Issue date: 2022 May
- Tim-3 and its role in regulating anti-tumor immunity.
- Authors: Das M, Zhu C, Kuchroo VK
- Issue date: 2017 Mar